MA50101A - Agents de modulation des fonctions de la bêta-caténine et méthodes associées - Google Patents

Agents de modulation des fonctions de la bêta-caténine et méthodes associées

Info

Publication number
MA50101A
MA50101A MA050101A MA50101A MA50101A MA 50101 A MA50101 A MA 50101A MA 050101 A MA050101 A MA 050101A MA 50101 A MA50101 A MA 50101A MA 50101 A MA50101 A MA 50101A
Authority
MA
Morocco
Prior art keywords
agents
related methods
modulating beta
catenin functions
catenin
Prior art date
Application number
MA050101A
Other languages
English (en)
Inventor
Gerard Hilinski
John Hanney Mcgee
Paula Ortet
Matthew Reiser Patton
So Youn Shim
Gregory L Verdine
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MA50101A publication Critical patent/MA50101A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050101A 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées MA50101A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762555519P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
MA50101A true MA50101A (fr) 2020-07-15

Family

ID=65635271

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050101A MA50101A (fr) 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées

Country Status (14)

Country Link
US (2) US11198713B2 (fr)
EP (1) EP3678683A4 (fr)
JP (1) JP2020533413A (fr)
KR (1) KR20200064075A (fr)
CN (1) CN111372942A (fr)
AU (1) AU2018329956A1 (fr)
BR (1) BR112020004555A2 (fr)
CA (1) CA3074838A1 (fr)
EA (1) EA202090513A1 (fr)
IL (1) IL273015A (fr)
MA (1) MA50101A (fr)
MX (1) MX2020002435A (fr)
SG (1) SG11202001162TA (fr)
WO (1) WO2019051327A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3746105A4 (fr) 2018-01-29 2022-05-18 Ohio State Innovation Foundation Inhibiteurs peptidyliques cycliques du domaine de liaison cal-pdz
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
AU2019384820B2 (en) 2018-11-21 2026-02-12 Endomet Biosciences, Inc. Compositions and methods for treating endometriosis
US20220315631A1 (en) * 2019-08-30 2022-10-06 Ohio State Innovation Foundation Stapled beta-catenin ligands
CA3186681A1 (fr) * 2020-07-22 2022-01-27 Brian Halbert WHITE Peptides agrafes et utilisations associees
BR112023025528A2 (pt) * 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes
US20260207704A1 (en) * 2022-12-15 2026-07-23 Parabilis Medicines, Inc. Stapled peptides and methods thereof
JP2026520144A (ja) * 2023-06-06 2026-06-22 パラビリス メディシンズ， インコーポレイテッド ステープルペプチドおよびその方法
WO2025265097A1 (fr) * 2024-06-20 2025-12-26 Parabilis Medicines, Inc. Peptides agrafés et procédés associés
WO2026038952A1 (fr) 2024-08-12 2026-02-19 Stichting Vu Peptides de liaison à bêta-caténine, peptidomimétiques et leurs utilisations

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ES2367475T3 (es) 1999-10-15 2011-11-03 Avatar Medical, L.L.C. Proteínas estabilizadas.
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
US7485630B2 (en) 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
WO2004093798A2 (fr) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
EP1680443B9 (fr) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Peptides stabilises structures en helice alpha et leurs utilisations
AU2005274616A1 (en) 2004-08-20 2006-02-23 Phylogica Limited Peptide inhibitors of c-Jun dimerization and uses thereof
JP2008510692A (ja) 2004-08-20 2008-04-10 ノボ ノルディスク アクティーゼルスカブ 薬学的に活性なインスリン受容体調節分子
CA2590750A1 (fr) 2004-12-20 2006-06-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Inhibiteurs d'homodimerisation de myd88
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (fr) 2007-03-28 2016-10-19 President and Fellows of Harvard College Polypeptides piqués
US10716828B2 (en) 2007-05-02 2020-07-21 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
WO2009020477A1 (fr) 2007-08-06 2009-02-12 Yale University Protéines miniatures modifiées
EP2208061B1 (fr) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Procédés et compositions pour moduler des polypeptides de la famille bcl-2
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
EP2356139A4 (fr) 2008-07-23 2013-01-09 Harvard College Ligature de polypeptides agrafés
US8524653B2 (en) 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3401684B1 (fr) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Modulateurs chimiques des polypeptides bax et bcl-2 pro-apoptotiques
EP3549951A3 (fr) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Procédés et compositions pour la modulation spécifique de mcl-1
US20100152103A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2010121288A1 (fr) 2009-04-22 2010-10-28 Walter And Eliza Hall Institute Of Medical Research Structure de la region c terminale de la chaîne α du recepteur d'insuline et de la chaîne α du recepteur de facteur de croissance de type insuline
WO2010132869A2 (fr) 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ligands mimétiques de peptide de domaine de boîte polo de kinase 1 de type polo et procédés d'utilisation
EP3698811A1 (fr) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Compositions de peptides viraux structurés et procédés d'utilisation
DE102009032902A1 (de) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
WO2011008260A2 (fr) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US8748570B2 (en) 2010-05-25 2014-06-10 Syngene Limited Insulin analogues
AU2011274474B2 (en) 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (fr) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Peptides de ciblage de la béta-caténine et leurs utilisations
EP2637680B1 (fr) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Thérapies du cancer
EP2651971A1 (fr) * 2010-12-14 2013-10-23 The United States of America, as Represented By the Secretery, Department of Health and Human Services Inhibiteurs peptidiques synthétiques de la voie wnt
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
CA2833171C (fr) * 2011-04-15 2021-08-31 Loren D. Walensky Ciblage d'une signalisation wnt deregulee dans le cancer a l'aide d'helices alpha de bcl-9 stabilisees
WO2012174423A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Polypeptides stabilisés comme régulateurs de fonction gtpase rab
WO2012174409A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Peptides maml variants stabilisés et leurs utilisations
CA3173988A1 (fr) 2011-10-11 2013-04-18 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones qui activent le bax pro-apoptotique
WO2013102211A2 (fr) 2011-12-29 2013-07-04 Walensky Loren D Hélices hybrides stabilisées antivirales
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
EP2901154B1 (fr) 2012-09-25 2018-11-21 The Walter and Eliza Hall Institute of Medical Research Structure d'insuline dans un complexe avec des régions terminales en n et en c de la chaîne alpha du récepteur de l'insuline
CA3113959A1 (fr) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Peptides agrafes bloques par la proline et leurs utilisations
WO2014055564A1 (fr) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
EP3782638A1 (fr) 2013-03-13 2021-02-24 President and Fellows of Harvard College Polypeptides piqués et agrafés et leurs utilisations
CA2906775A1 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides bh4 stabilises et leurs utilisations
WO2014144148A1 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides sos1 stabilisés
WO2014151369A2 (fr) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Peptide d'ezh2 stabilisé
WO2014197821A1 (fr) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Protéines de fusion à homéodomaine et leurs utilisations
WO2014201370A1 (fr) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
EP3270945A4 (fr) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Peptides de liaison à mcl-1 sélectifs
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
WO2017062518A1 (fr) * 2015-10-05 2017-04-13 Wntrx Pharmaceuticals Inc. Peptides bcl9 stabilisés pour le traitement de la signalisation wnt aberrante
US20190048038A1 (en) * 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) * 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
CA3159729A1 (fr) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies utiles pour evaluer la permeabilite
EP4121082A4 (fr) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. Peptides hélicoïdaux agrafés et leurs utilisations
CN116113621A (zh) 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
CA3186681A1 (fr) 2020-07-22 2022-01-27 Brian Halbert WHITE Peptides agrafes et utilisations associees
BR112023025528A2 (pt) 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes

Also Published As

Publication number Publication date
US11198713B2 (en) 2021-12-14
US20200247858A1 (en) 2020-08-06
CA3074838A1 (fr) 2019-03-14
EP3678683A4 (fr) 2021-07-14
US11834482B2 (en) 2023-12-05
CN111372942A (zh) 2020-07-03
WO2019051327A3 (fr) 2019-04-18
SG11202001162TA (en) 2020-03-30
EP3678683A2 (fr) 2020-07-15
IL273015A (en) 2020-04-30
US20220213154A1 (en) 2022-07-07
EA202090513A1 (ru) 2020-08-24
BR112020004555A2 (pt) 2020-09-24
MX2020002435A (es) 2020-09-22
JP2020533413A (ja) 2020-11-19
WO2019051327A2 (fr) 2019-03-14
KR20200064075A (ko) 2020-06-05
AU2018329956A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL271149A (en) Compounds for modulating s1p1 activity and methods of using the same
IL273015A (en) Beta-catenin functional modulators and methods thereof
EP3617784A4 (fr) Dispositif de modulation de lumière
PL3661925T3 (pl) Nowe związki sulfonamidowo karboksyamidowe
EP3353303A4 (fr) Compositions et méthodes de modulation de l'expression de l'ataxine 3
EP3484524A4 (fr) Composés et procédés de modulation de smn2
IL286681A (en) Compounds and methods for modulating ube3a-ats
DK3743406T3 (da) Tmem16a modulatorer
EP3295578A4 (fr) Système de modulation de l'espace temps-fréquence orthogonal
EP3307782C0 (fr) Anticorps pour moduler une réponse immunitaire
IL263045B (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3422567A4 (fr) Amplificateur de modulation de charge
EP3463355A4 (fr) Modulateurs de dux4 pour la régulation de la fonction musculaire
FR3027414B1 (fr) Modulateur de phase electro­optique et procede de modulation
EP3605205A4 (fr) Modulateur optique iq
EP3349749A4 (fr) Compositions et méthodes de modulation de l'expression de fmr1
EP3876747A4 (fr) Procédés de modulation de métabolites gastro-intestinaux
EP3405188A4 (fr) Traitement pour la modulation du microbiote intestinal
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
MA54386A (fr) Modulateurs de trex1
EP3477362A4 (fr) Modulateur électro-optique
EP3551629A4 (fr) Oxabicycloheptanes pour la modulation de la réponse immunitaire
EP3675945A4 (fr) Dispositif de type sphinctérotome et méthodes et utilisations associées
EP3377053A4 (fr) Méthode de modulation de ribonucléotide réductase
EP3607653C0 (fr) Modulation polaire utilisant un mode de produit